Plant Name: Zanthoxylum spinosum
Collective Molecular Activities at 10μM Activity Cutoff
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
| Cytochrome P450 Enzymes: |
|---|
Detailed Information of Human Protein Targets
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 2.630E-14 | 5.727E-10 | CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4 |
| BP | GO:0050896; response to stimulus | GO:0042738; exogenous drug catabolic process | 3.451E-12 | 3.758E-08 | CYP1A2, CYP2A6, CYP2C19, CYP2C9, CYP3A4 |
| MF | GO:0003824; catalytic activity | GO:0008395; steroid hydroxylase activity | 6.839E-12 | 4.964E-08 | CYP2A13, CYP2A6, CYP2C19, CYP2C9, CYP2D6, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0008202; steroid metabolic process | 4.416E-11 | 1.603E-07 | AKR1B10, CYP1A2, CYP2A6, CYP2C19, CYP2C9, CYP2D6, CYP3A4, NPC1, NR1H4 |
| MF | GO:0005488; binding | GO:0019825; oxygen binding | 4.098E-11 | 1.603E-07 | CYP1A2, CYP2A13, CYP2C19, CYP2C9, CYP2D6, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 8.789E-11 | 2.392E-07 | CYP1A2, CYP2A13, CYP2A6, CYP2C19, CYP2C9 |
| MF | GO:0005488; binding | GO:0020037; heme binding | 5.015E-10 | 6.825E-07 | CYP1A2, CYP2A13, CYP2A6, CYP2C19, CYP2C9, CYP2D6, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0070989; oxidative demethylation | 1.734E-09 | 2.092E-06 | CYP1A2, CYP2C9, CYP2D6, CYP3A4 |
| MF | GO:0005488; binding | GO:0005506; iron ion binding | 2.399E-09 | 2.462E-06 | CYP1A2, CYP2A13, CYP2A6, CYP2C19, CYP2C9, CYP2D6, CYP3A4 |
| MF | GO:0003824; catalytic activity | GO:0008392; arachidonic acid epoxygenase activity | 8.296E-09 | 6.948E-06 | CYP2A13, CYP2A6, CYP2C19, CYP2C9 |
| MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 1.090E-08 | 7.912E-06 | CYP1A2, CYP2C9, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0006805; xenobiotic metabolic process | 1.254E-08 | 8.809E-06 | CYP1A2, CYP2A13, CYP2C19, CYP2C9, CYP2D6, CYP3A4 |
| MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 3.068E-08 | 1.856E-05 | CYP1A2, CYP2A13, CYP2D6, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0009804; coumarin metabolic process | 9.510E-08 | 5.051E-05 | CYP2A13, CYP2A6, CYP2D6 |
| BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 3.251E-07 | 1.573E-04 | CYP1A2, CYP2C19, CYP2C9 |
| MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 1.227E-06 | 5.565E-04 | CA12, CA7, CA9 |
| MF | GO:0003824; catalytic activity | GO:0008389; coumarin 7-hydroxylase activity | 2.026E-06 | 8.825E-04 | CYP2A13, CYP2A6 |
| BP | GO:0008152; metabolic process | GO:0009822; alkaloid catabolic process | 6.074E-06 | 2.362E-03 | CYP2D6, CYP3A4 |
| BP | GO:0009987; cellular process | GO:0038183; bile acid signaling pathway | 6.074E-06 | 2.362E-03 | GPBAR1, NR1H4 |
| MF | GO:0060089; molecular transducer activity | GO:0038181; bile acid receptor activity | 6.074E-06 | 2.362E-03 | GPBAR1, NR1H4 |
| BP | GO:0009987; cellular process | GO:1902202; regulation of hepatocyte growth factor receptor signaling pathway | 1.214E-05 | 4.479E-03 | PTPN1, PTPN2 |
| BP | Unclassified; | GO:0032846; positive regulation of homeostatic process | 1.655E-05 | 5.908E-03 | CA7, MAPK1, NPC1, NR1H4, PLA2G1B |
| BP | GO:0050896; response to stimulus | GO:0071417; cellular response to organonitrogen compound | 1.812E-05 | 6.362E-03 | CASP7, MAPK1, NFKB1, NR1H4, PLA2G1B, TSHR |
| BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 1.886E-05 | 6.519E-03 | CA12, CA7, CA9 |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10, ordered by adjusted p-value
Detailed Information of Enriched KEGG Pathways
| Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|
| hsa00982 | Drug metabolism - cytochrome P450_Homo sapiens_hsa00982 | 4.791E-10 | 3.073E-08 | CYP2C9; CYP2A6; CYP2D6; CYP1A2; CYP3A4; CYP2C19 |
| hsa00591 | Linoleic acid metabolism_Homo sapiens_hsa00591 | 4.279E-10 | 3.073E-08 | CYP2C9; PLA2G1B; CYP1A2; CYP3A4; CYP2C19 |
| hsa00980 | Metabolism of xenobiotics by cytochrome P450_Homo sapiens_hsa00980 | 6.778E-10 | 3.073E-08 | CYP2C9; CYP2A6; CYP2A13; CYP2D6; CYP1A2; CYP3A4 |
| hsa05204 | Chemical carcinogenesis_Homo sapiens_hsa05204 | 1.382E-09 | 4.700E-08 | CYP2C9; CYP2A6; CYP2A13; CYP1A2; CYP3A4; CYP2C19 |
| hsa00830 | Retinol metabolism_Homo sapiens_hsa00830 | 2.875E-08 | 7.821E-07 | CYP2C9; CYP2A6; CYP1A2; ALDH1A1; CYP3A4 |
| hsa05133 | Pertussis_Homo sapiens_hsa05133 | 3.488E-06 | 6.776E-05 | CASP7; CASP1; MAPK1; NFKB1 |
| hsa01100 | Metabolic pathways_Homo sapiens_hsa01100 | 3.078E-05 | 4.186E-04 | CYP2C9; CYP2A6; AKR1B10; PLA2G1B; CYP1A2; ALDH1A1; CYP2C19; CYP3A4; HSD17B10 |
| hsa04726 | Serotonergic synapse_Homo sapiens_hsa04726 | 1.720E-05 | 2.849E-04 | CYP2C9; CYP2D6; MAPK1; CYP2C19 |
| hsa05134 | Legionellosis_Homo sapiens_hsa05134 | 6.140E-05 | 7.591E-04 | CASP7; CASP1; NFKB1 |
| hsa00590 | Arachidonic acid metabolism_Homo sapiens_hsa00590 | 8.794E-05 | 9.200E-04 | CYP2C9; PLA2G1B; CYP2C19 |
| hsa04621 | NOD-like receptor signaling pathway_Homo sapiens_hsa04621 | 6.835E-05 | 7.747E-04 | CASP1; MAPK1; NFKB1 |
| hsa00910 | Nitrogen metabolism_Homo sapiens_hsa00910 | 1.649E-06 | 3.738E-05 | CA12; CA7; CA9 |
| hsa04668 | TNF signaling pathway_Homo sapiens_hsa04668 | 4.798E-04 | 4.350E-03 | CASP7; MAPK1; NFKB1 |
| hsa05132 | Salmonella infection_Homo sapiens_hsa05132 | 2.327E-04 | 2.260E-03 | CASP1; MAPK1; NFKB1 |
| hsa04210 | Apoptosis_Homo sapiens_hsa04210 | 9.674E-04 | 8.223E-03 | CASP7; MAPK1; NFKB1 |
| hsa05164 | Influenza A_Homo sapiens_hsa05164 | 1.837E-03 | 1.348E-02 | CASP1; MAPK1; NFKB1 |
| hsa05010 | Alzheimer's disease_Homo sapiens_hsa05010 | 1.634E-03 | 1.308E-02 | CASP7; MAPK1; HSD17B10 |
| hsa04024 | cAMP signaling pathway_Homo sapiens_hsa04024 | 2.646E-03 | 1.760E-02 | MAPK1; NFKB1; TSHR |
| hsa05203 | Viral carcinogenesis_Homo sapiens_hsa05203 | 2.878E-03 | 1.760E-02 | POLB; MAPK1; NFKB1 |
| hsa04014 | Ras signaling pathway_Homo sapiens_hsa04014 | 3.834E-03 | 1.932E-02 | PLA2G1B; MAPK1; NFKB1 |
| hsa05221 | Acute myeloid leukemia_Homo sapiens_hsa05221 | 2.876E-03 | 1.760E-02 | MAPK1; NFKB1 |
| hsa00983 | Drug metabolism - other enzymes_Homo sapiens_hsa00983 | 1.883E-03 | 1.348E-02 | CYP2A6; CYP3A4 |
| hsa04010 | MAPK signaling pathway_Homo sapiens_hsa04010 | 5.302E-03 | 2.121E-02 | MAPK1; NFKB1; CDC25B |
| hsa05212 | Pancreatic cancer_Homo sapiens_hsa05212 | 3.836E-03 | 1.932E-02 | MAPK1; NFKB1 |
| hsa04917 | Prolactin signaling pathway_Homo sapiens_hsa04917 | 4.547E-03 | 1.977E-02 | MAPK1; NFKB1 |
| hsa04662 | B cell receptor signaling pathway_Homo sapiens_hsa04662 | 4.671E-03 | 1.977E-02 | MAPK1; NFKB1 |
| hsa00140 | Steroid hormone biosynthesis_Homo sapiens_hsa00140 | 2.977E-03 | 1.760E-02 | CYP1A2; CYP3A4 |
| hsa05220 | Chronic myeloid leukemia_Homo sapiens_hsa05220 | 4.671E-03 | 1.977E-02 | MAPK1; NFKB1 |
| hsa05206 | MicroRNAs in cancer_Homo sapiens_hsa05206 | 8.070E-03 | 2.959E-02 | MAPK1; NFKB1; CDC25B |
| hsa04623 | Cytosolic DNA-sensing pathway_Homo sapiens_hsa04623 | 3.611E-03 | 1.932E-02 | CASP1; NFKB1 |
| hsa05131 | Shigellosis_Homo sapiens_hsa05131 | 3.723E-03 | 1.932E-02 | MAPK1; NFKB1 |
| hsa05215 | Prostate cancer_Homo sapiens_hsa05215 | 6.865E-03 | 2.668E-02 | MAPK1; NFKB1 |
| hsa04976 | Bile secretion_Homo sapiens_hsa04976 | 4.425E-03 | 1.977E-02 | NR1H4; CYP3A4 |
| hsa04933 | AGE-RAGE signaling pathway in diabetic complications_Homo sapiens_hsa04933 | 8.762E-03 | 3.002E-02 | MAPK1; NFKB1 |
| hsa05140 | Leishmaniasis_Homo sapiens_hsa05140 | 4.671E-03 | 1.977E-02 | MAPK1; NFKB1 |
| hsa04914 | Progesterone-mediated oocyte maturation_Homo sapiens_hsa04914 | 8.268E-03 | 2.959E-02 | MAPK1; CDC25B |
| hsa04520 | Adherens junction_Homo sapiens_hsa04520 | 4.797E-03 | 1.977E-02 | PTPN1; MAPK1 |
| hsa04066 | HIF-1 signaling pathway_Homo sapiens_hsa04066 | 9.099E-03 | 3.002E-02 | MAPK1; NFKB1 |
| hsa00564 | Glycerophospholipid metabolism_Homo sapiens_hsa00564 | 7.788E-03 | 2.942E-02 | ACHE; PLA2G1B |
| hsa04725 | Cholinergic synapse_Homo sapiens_hsa04725 | 1.050E-02 | 3.174E-02 | ACHE; MAPK1 |
| hsa04660 | T cell receptor signaling pathway_Homo sapiens_hsa04660 | 9.269E-03 | 3.002E-02 | MAPK1; NFKB1 |
| hsa04620 | Toll-like receptor signaling pathway_Homo sapiens_hsa04620 | 9.615E-03 | 3.041E-02 | MAPK1; NFKB1 |
| hsa05142 | Chagas disease (American trypanosomiasis)_Homo sapiens_hsa05142 | 9.269E-03 | 3.002E-02 | MAPK1; NFKB1 |
| hsa04931 | Insulin resistance_Homo sapiens_hsa04931 | 1.014E-02 | 3.135E-02 | PTPN1; NFKB1 |
| hsa05145 | Toxoplasmosis_Homo sapiens_hsa05145 | 1.180E-02 | 3.383E-02 | MAPK1; NFKB1 |
| hsa04722 | Neurotrophin signaling pathway_Homo sapiens_hsa04722 | 1.219E-02 | 3.383E-02 | MAPK1; NFKB1 |
| hsa04270 | Vascular smooth muscle contraction_Homo sapiens_hsa04270 | 1.219E-02 | 3.383E-02 | PLA2G1B; MAPK1 |
| hsa04380 | Osteoclast differentiation_Homo sapiens_hsa04380 | 1.461E-02 | 3.951E-02 | MAPK1; NFKB1 |
| hsa05161 | Hepatitis B_Homo sapiens_hsa05161 | 1.767E-02 | 4.534E-02 | MAPK1; NFKB1 |
| hsa04071 | Sphingolipid signaling pathway_Homo sapiens_hsa04071 | 1.219E-02 | 3.383E-02 | MAPK1; NFKB1 |
| hsa04932 | Non-alcoholic fatty liver disease (NAFLD)_Homo sapiens_hsa04932 | 1.882E-02 | 4.741E-02 | CASP7; NFKB1 |
| hsa05160 | Hepatitis C_Homo sapiens_hsa05160 | 1.482E-02 | 3.951E-02 | MAPK1; NFKB1 |
| hsa04910 | Insulin signaling pathway_Homo sapiens_hsa04910 | 1.611E-02 | 4.213E-02 | PTPN1; MAPK1 |
| hsa00232 | Caffeine metabolism_Homo sapiens_hsa00232 | 1.885E-05 | 2.849E-04 | CYP2A6; CYP1A2 |
Human Diseases Associated with the Target Proteins of the Plant (Activity≤10μM)
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Linked Targets |
|---|---|---|---|
| I00-I99: Diseases of the circulatory system | Arteriosclerosis | I70 | PLA2G1B |
| NA: NA | Colour dead tissues | NA | PTPN1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Inflammatory and pruritic manifestations of moderate to severe corticosteroid-responsive dermatoses of the scalp | L20-L30 | PLA2G1B |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poisoning due to pesticides and chemicals | T36-T50 | ACHE |
| N00-N99: Diseases of the genitourinary system | Urinary dysfunction | N39.3-N39.4 | ACHE |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poison intoxication | T36-T50 | ACHE |
| A00-B99: Certain infectious and parasitic diseases | Infections | A00-B99 | PTPN1 |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | CA9; MAPK1 |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis diagnosis | G70.0 | ACHE |
| C00-D49: Neoplasms | Cancer | C00-C96 | CA9; MAPK1; NFKB1; ACHE; CDC25B |
| C00-D49: Neoplasms | Clear cell renal cell carcinoma | C64 | CA9 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | CASP1; PLA2G1B |
| K00-K95: Diseases of the digestive system | Xerostomia | K11.7, R68.2 | ACHE |
| I00-I99: Diseases of the circulatory system | Restenosis | I51.89 | MAPK1 |
| C00-D49: Neoplasms | Renal cancer | C64 | CA9 |
| C00-D49: Neoplasms | Breast cancer | C50 | CA9 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Fibrosis | L90.5 | CASP1 |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | ACHE |
| A00-B99: Certain infectious and parasitic diseases | Pediculus humanus capitis | B85.0 | ACHE |
| L00-L99: Diseases of the skin and subcutaneous tissue | Contact dermatitis | L23, L24, L25 | PLA2G1B |
| J00-J99: Diseases of the respiratory system | Allergic rhinitis | J00, J30, J31.0, T78.4 | PLA2G1B |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | ACHE; ACHE; ACHE |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | ACHE |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | ACHE |
| L00-L99: Diseases of the skin and subcutaneous tissue | Pruritus | L29 | PLA2G1B |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | CYP3A4; ACHE |
| A00-B99: Certain infectious and parasitic diseases | Leishmaniasis | B55.0 | PLA2G1B |
| G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | ACHE |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | PTPN1; PTPN1; GPBAR1; NFKB1 |
| C00-D49: Neoplasms | Thyroid cancer diagnosis | C73 | TSHR |
| C00-D49: Neoplasms | Thyroid cancer | C73 | TSHR |
| H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | ACHE |
| NA: NA | Early satiation associated with functional dyspepsia | NA | ACHE |
| E00-E89: Endocrine, nutritional and metabolic diseases | Obesity | E66 | PTPN1 |
| C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | PLA2G1B |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CYP2D6 |
| NA: NA | Upper abdominal bloating | NA | ACHE |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | PTPN1 |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis | G70.0 | ACHE |
| C00-D49: Neoplasms | Lymphoma | C81-C86 | CA9 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Nerve injury | T14.4 | PLA2G1B |
| A00-B99: Certain infectious and parasitic diseases | Visceral leishmaniasis | B55.0 | PLA2G1B |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | ACHE |
| G00-G99: Diseases of the nervous system G00-G99 | Epileptic seizures | G40, P90, R56 | ACHE |
| G00-G99: Diseases of the nervous system G00-G99 | Epilepsy | G40 | CASP1 |
| A00-B99: Certain infectious and parasitic diseases | Malaria | B54 | CYP2D6 |
| W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Diagnostic test to differentiate primary and secondary hypothyroidism | W88 | TSHR |
| G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | ACHE |
| G00-G99: Diseases of the nervous system G00-G99 | Migraine | G43 | CYP2D6 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Allergy | T78.4 | PLA2G1B |
| L00-L99: Diseases of the skin and subcutaneous tissue | Inflammatory and pruritic manifestations of corticosteroid responsive dermatoses | L20-L30 | PLA2G1B |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mild cognitive impairment | F06.7 | ACHE |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | PLA2G1B |
| J00-J99: Diseases of the respiratory system | Asthma | J45 | PLA2G1B |
| E00-E89: Endocrine, nutritional and metabolic diseases | Metabolic disorders | E70-E89 | GPBAR1 |
| A00-B99: Certain infectious and parasitic diseases | Bacterial infections | A00-B99 | CYP2C9 |
| A00-B99: Certain infectious and parasitic diseases | Helminth infection | A00-B99 | ACHE |